摘要
目的:观察我院肾移植术后患者服用咪唑立宾后血尿酸的变化规律及转归,为临床安全用药提供参考。方法:采用回顾性调查分析方法,收集我院2017年10月-2019年3月肾移植中心术后使用咪唑立宾的病例,对患者的一般情况、初始免疫抑制方案、咪唑立宾用药原因、血尿酸水平、干预措施等进行描述性统计分析。结果:共收集到18例患者,因不能耐受霉酚酸类不良反应或需降低免疫抑制强度而应用咪唑立宾。用药期间,13例患者用药后2~3 d即出现血尿酸水平升高,其中6例因高尿酸血症予以非布司他治疗,治疗3~7 d后血尿酸水平降至正常范围内。结论:血尿酸升高为咪唑立宾的常见不良反应,肾移植术后患者在使用该药期间应注意监测血尿酸水平,如需治疗咪唑立宾相关的高尿酸血症,可选择非布司他。
Objective:To study the influence of mizoribine on serum uric acid in order to provide references for the rational use of mizoribine.Methods:Data of patients using mizoribine after renal transplantation from October 2017 to March 2019 in our hospital were collected.The general situation,initial immunosuppression drugs,reason of using mizoribine,the level of serum uric acid,the intervention measures were retrospectively analyzed.Results:A total of 18 cases were collected.Mizoribine was used for patients who could not tolerate the adverse reaction of mycophenolic acid or who needed to reduce the intensity of immunosuppressive agents.The levels of serum uric acid in 13 patients were elevated in 2 or 3 days after medication.6 cases with mizoribine induced hyperuricemia were treated with febuxostat.And the levels of serum uric acid dropped to the normal range in 3 to 7 days after the treatment.Conclusion:Elevated serum uric acid was a common adverse reaction of mizoribine,which should be closely monitored during medication.Febuxostat was effective for mizoribine-related hyperuricemia.
作者
侯文婧
温爱萍
林俊
HOU Wen-jing;WEN Ai-ping;LIN Jun(Department of Pharmacy,Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 100050,China;Department of Urology,Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 100050,China)
出处
《中国药物应用与监测》
CAS
2019年第4期196-198,203,共4页
Chinese Journal of Drug Application and Monitoring
基金
首都特色–无手助袖套装置小切口后腹膜腔镜活体供肾切取术对供者围手术期及远期生活质量的改善研究（Z161100000516147)
关键词
咪唑立宾
肾移植
血尿酸
非布司他
药物不良反应
Mizoribine
Kidney transplant
Serum uric acid
Febuxostat
Adverse drug reaction
